Frovocimab
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9[1].
Product Specifications
CAS Number
1643672-70-1
Product Name Alternative
LY 3015014
UNSPSC
12352203
Target
PCSK9
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/frovocimab.html
Purity
99.87
Solubility
10 mM in DMSO
Smiles
[Frovocimab]
Molecular Weight
(146.38 kDa)
References & Citations
[1]Krista M Schroeder, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015 Nov;56 (11) :2124-32.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
